| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440749 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
A survival benefit of cisplatin dose >200Â mg/m2 is evident for HPVâ LAHNC patients, but not for HPV+ cohort overall, although the T4 or N3 subset may benefit from a higher cumulative cisplatin dose.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anna Spreafico, Shao Hui Huang, Wei Xu, Roberta Granata, Chen-Shin Liu, John N. Waldron, Eric Chen, Jolie Ringash, Andrew Bayley, Kelvin K.W. Chan, Andrew J. Hope, John Cho, Albiruni A.R. Razak, Aaron Hansen, Raymond Jang, Bayardo Perez-Ordonez,